Wed, Jul 30, 2014, 12:31 AM EDT - U.S. Markets open in 8 hrs 59 mins

Recent

% | $
Click the to save as a favorite.

Momenta Pharmaceuticals Inc. Message Board

  • ding_king2000 ding_king2000 Mar 21, 2014 9:44 AM Flag

    Teva files to extend patent which BLOCKS MNTA from introducing generic formulation until 2016

    Didn't see this coming..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • cmhe@prodigy.net cmhe Mar 21, 2014 11:05 AM Flag

      Teva will always try to protect , The BIG deal is still that the FDA has not given any green light on MNTA's formulation. From my knowledge they are both completely independent events.

      • 1 Reply to cmhe
      • If the Supreme Court decides tomorrow, 3/28, to hear Teva's appeal of the previous decision to invalidate some of their Copaxone patents I'd be surprised. Teva would have to make a very compelling argument that the lower court's decision was a mistake. If the appeal is rejected the next hurdle certainly is FDA approval. The FDA accepted MNTA's characterization process for producing generics in the Lovenex decision as yielding an approvable duplicate my guess is that their generic Copaxane would be as well.

        Sentiment: Buy

 
MNTA
10.96+0.31(+2.91%)Jul 29 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.